DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma

Information source: Erkim Ilac A.S.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Multiple Myeloma

Intervention: Thalidomide (Drug); Melphalan+Prednisolone (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Cigdem Sahinbas YILMAZ

Official(s) and/or principal investigator(s):
Meral Beksac, Prof.Dr., Principal Investigator, Affiliation: Ankara University
Rauf Haznedar, Prof.Dr., Principal Investigator, Affiliation: Gazi University


This is a multi-centre Phase III randomized controlled study of patients with multiple myeloma (MM). Eligible patients who are not candidates for transplantation will be randomized to receive eight courses of Melphalan/Prednisolone with or without Thalidomide treatment. Thalidomide will be initiated at the dose of 100 mg/day and maintained at 100 mg/day. The patients will be assessed for any responses at the end of 2nd, 4th, 6th and 8th cycles of treatment. The toxicities will be assessed at monthly intervals. Patients will be assessed for the: 1. Incidence and grade of any toxicity 2. Level of maximum disease response 3. Time to disease progression 4. Time to death

Clinical Details

Official title: Phase III Trial Comparing Treatment With Melphalan+Prednisolon (MP) With Melphalan+Prednisolon+Thalidomide (MPT) for Previously Untreated Elderly Patients With Multiple Myeloma

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: response rate

Secondary outcome:

time to relapse

overall survival

Detailed description: This trial will include patients who are not candidates for transplantation and above the age of 55. Treatment cycles will include (MP)melphalan (9 mg /sq. m/day d1-4), prednisolone (60 mg/sq. m/d,d1-4) every six weeks for maximum 8 cycles. Patients will be randomised to (MPT) Thalidomide (1: 1) 100 mg/day continuously. Cross-over to MPT is allowed if insufficient response is obtained in the MP arm. response will be evaluated every other cycle. At the end of 12 months of treatment patients will be followed until progress and death. Second line treatment is not defined.


Minimum age: 55 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Age above 55 years old.

- Diagnosis of MM (Appendix A) and staging (Appendix B), previously untreated.

- Performance status ECOG, 0, 1, or 2 (Appendix C).

- Written informed consent to the study medications and bone marrow biopsy at

diagnosis, 12 weeks and 6 months and/or off-study assessment.

- Women who are pregnant or lactating at the time of diagnosis are ineligible. All

women of child-bearing potential must have a negative pregnancy test within 24hrs of commencing the thalidomide and must take adequate precautions to prevent pregnancy and should not plan on conceiving children during the treatment program:

- Adequate precautions are defined as "at least one highly effective method i. e.,

IUD, hormonal (birth control pills, injections, or implants), tubal ligation, partner's vasectomy AND one additional effective method i. e., latex condom, diaphragm, cervical cap".

- Women becoming pregnant on protocol will be removed immediately from protocol.

- Male patients (including patients having had a vasectomy) must use barrier

contraception during and for four weeks after completing the thalidomide.

- Patients remain eligible in the presence of abnormal renal function and/or liver

function at time of enrollment.

- Absence of severe dementia, able to take medication at home.

- Absence of systemic disorders (gastrointestinal, pulmonary, cardiac and

neurological). Exclusion Criteria:

- Asymptomatic myeloma or solitary plasmacytoma of bone or extramedullary plasmacytoma

(without evidence of myeloma).

- Previous or concurrent active malignancies, except surgically removed basal cell

carcinoma of the skin or other in situ carcinomas.

- Previous treatment for myeloma, except minimal local radiotherapy to relieve bone


- Other illnesses which would preclude chemotherapy administration or patient


- Any other serious medical or psychiatric illness which would prevent informed


- Peripheral neuropathy > NCI criteria grade 2.

- Pregnant or lactating women and patients of childbearing age who refuse to use


- History of hypersensitivity to thalidomide or any component of the medications.

Locations and Contacts

Baskent University School of Medicine Education and Research Hospital, Hematology Department, Adana, Turkey

Ankara Numune Education and Research Hospital,Hematology Department, Ankara, Turkey

Ankara University School of Medicine, Hematology Department, Ankara, Turkey

Gazi University School of Medicine, Hematology Department, Ankara, Turkey

Hacettepe University School of Medicine, Hematology Department, Ankara, Turkey

Akdeniz University School of Medicine , Hematology Department, Antalya 07070, Turkey

Uludag University School of Medicine, Hematology Department, Bursa, Turkey

Osmangazi University School of Medicine , Hematology Department, Eskisehir, Turkey

Marmara University School of Medicine, Hematology Department, Istanbul, Turkey

Additional Information

Starting date: March 2006
Last updated: August 14, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017